BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Upgraded to “Sell” at Wall Street Zen

Wall Street Zen upgraded shares of BridgeBio Oncology Therapeutics (NASDAQ:BBOT) from a strong sell rating to a sell rating in a research report sent to investors on Saturday.

BBOT has been the topic of several other reports. Canaccord Genuity Group began coverage on shares of BridgeBio Oncology Therapeutics in a research report on Monday, May 11th. They issued a “buy” rating and a $23.00 price objective on the stock. UBS Group cut shares of BridgeBio Oncology Therapeutics to an “overweight” rating in a research note on Wednesday, July 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a research note on Thursday, June 18th. JPMorgan Chase & Co. began coverage on shares of BridgeBio Oncology Therapeutics in a report on Wednesday, July 8th. They issued an “overweight” rating and a $27.00 price target on the stock. Finally, Oppenheimer assumed coverage on shares of BridgeBio Oncology Therapeutics in a report on Monday, June 22nd. They issued an “outperform” rating and a $22.00 price target on the stock. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $24.80.

BridgeBio Oncology Therapeutics Price Performance

BBOT stock opened at $8.56 on Friday. The firm has a market cap of $685.74 million, a price-to-earnings ratio of -4.18 and a beta of 0.39. BridgeBio Oncology Therapeutics has a 1-year low of $7.00 and a 1-year high of $14.87. The business’s 50 day simple moving average is $8.16.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($526.11) earnings per share for the quarter. As a group, research analysts predict that BridgeBio Oncology Therapeutics will post -2.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BBOT. CIBC Private Wealth Group LLC acquired a new stake in BridgeBio Oncology Therapeutics during the fourth quarter worth about $63,000. Persistent Asset Partners Ltd acquired a new position in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at approximately $107,000. Squarepoint Ops LLC acquired a new position in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at approximately $144,000. Quadrature Capital Ltd bought a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter worth approximately $162,000. Finally, BIT Capital GmbH bought a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter worth approximately $313,000. Institutional investors and hedge funds own 54.89% of the company’s stock.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.